Patents by Inventor Shinya Minatoguchi

Shinya Minatoguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190307806
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 10, 2019
    Applicants: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Patent number: 10376544
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: August 13, 2019
    Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Publication number: 20180050067
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Application
    Filed: November 3, 2017
    Publication date: February 22, 2018
    Applicants: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Patent number: 9844570
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: December 19, 2017
    Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Publication number: 20170266758
    Abstract: A laser marker has: a controller configured to oscillate a laser beam; and a head configured to scan a machining surface of a machining target with the laser light. The controller is configured to transmit, to the image processing apparatus, a command for instructing the image processing apparatus to perform a predetermined scene, when the controller is set to cause the image processing apparatus to perform the scene. When the command is received, the image processing apparatus is configured to calculate a deviation amount of the machining target relative to a reference position using image data of an image of the machining target captured by the marker head and to notify the deviation amount to the controller. The controller is configured to correct a position to be scanned with the laser beam based on the deviation amount and then cause the marker head to perform the scanning.
    Type: Application
    Filed: January 17, 2017
    Publication date: September 21, 2017
    Inventors: Hiroshi FUKUI, Yoshihiro FUTAGAMI, Shinya MINATOGUCHI, Yoshimitsu ASHIHARA, Tatsunori SAKAMOTO
  • Publication number: 20150196600
    Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.
    Type: Application
    Filed: August 15, 2013
    Publication date: July 16, 2015
    Applicant: TOHOKU UNIVERSITY
    Inventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
  • Publication number: 20150064237
    Abstract: The present invention provides a pharmaceutical composition for treating infarction, such as myocardial infarction or cerebral infarction, with a method that is different from conventional therapeutic methods that use a thrombolytic agent or balloon therapy. An autophagy enhancer such as hsa-miR-145 is used as the active ingredient of the pharmaceutical composition for treating infarction. In particular, an autophagy enhancer such as hsa-miR-145 is used in a liposomal state as an active ingredient of the pharmaceutical composition for treating infarction.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 5, 2015
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., GIFU UNIVERSITY
    Inventors: Shinya Minatoguchi, Yukihiro Akao
  • Publication number: 20110054179
    Abstract: The present invention provides a highly safe pharmaceutical preparation effective for diseases caused by MMP-2 and/or MMP-9. The pharmaceutical preparation contains, as an active ingredient, at least one member selected from the group consisting of thiazole derivatives represented by Formula (1): wherein R1 represents a phenyl group that may have 1 to 3 lower alkoxy groups as substituents on the phenyl ring, and R2 represents a pyridyl group that may have 1 to 3 carboxyl groups as substituents on the pyridine ring, and salts thereof. Such thiazole derivatives have MMP-2 and/or MMP-9 inhibitory activity.
    Type: Application
    Filed: March 13, 2009
    Publication date: March 3, 2011
    Inventors: Shinya Minatoguchi, Yasushi Ohno, Youichi Yabuuchi, Kounori Kotosai, Hisashi Nagamoto